Bill > HF3756

This bill modifies the existing Insulin Safety Net Program in Minnesota by defining "covered insulin" as any drug prescribed by a practitioner that contains insulin for treating diabetes, excluding those solely for intravenous use, and clarifies that manufacturers with $2 million or less in annual covered insulin sales in Minnesota are exempt from certain program requirements, while also exempting covered insulin products with a wholesale acquisition cost of $8 or less per milliliter from the program. It also establishes a $100,000 annual registration fee for insulin manufacturers, with an exemption for those whose covered insulin sales represent less than five percent of the total market share in Minnesota, and repeals a section requiring surveys on program satisfaction.

Health and Social Services

https://www.revisor.mn.gov/bills/94/2026/0/HF/3756/